Product Reports Resources Pricing Login Book a demo

Oviva Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2021

A movement to improve women's experience of aging through biomedical research, development and advocacy MoreLess

Oviva Therapeutics is a pioneering startup that is developing first-of-its-kind therapeutics to enhance ovarian function and extend the healthspan of women. The company operates in the healthcare and biotechnology market, specifically focusing on women's health. The business model of Oviva Therapeutics revolves around the research, development, and commercialization of novel therapeutics that target ovarian function and longevity.

The company's primary clients are women who are experiencing or are at risk of age-related decline in ovarian function, which can lead to adverse health outcomes. Oviva Therapeutics aims to address this issue by developing innovative treatments that can extend the healthspan of women, thereby improving their overall health, well-being, and longevity.

The company generates revenue through the development and sale of these therapeutics. As the company's therapeutics are first-in-class, they have the potential to capture a significant market share in the women's health sector, providing a substantial revenue stream for the company.

Oviva Therapeutics is led by Daisy Robinton, PhD, who serves as the CEO and Co-Founder. The company is committed to not only developing effective therapeutics but also to elevating the broader conversation around women's health and building a coalition to drive this vision forward.

Keywords: Women's Health, Ovarian Function, Healthspan Extension, Therapeutics, Biotechnology, Healthcare, Age-Related Decline, Novel Treatments, Longevity, Oviva Therapeutics.

Company overview

Oviva Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2021
Headquarters
New York City, United States
Employees
1
Open positions
None listed
Dealroom signal
55.0
client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelSaaSindustryHealthsectorBiotechnologysectorSpinoutsectorFemtechsectorSustainable Development GoalssectorBiotech and PharmasectorLongevitysectorDT and LSsectorscience-based

Valuation & funding

Oviva Therapeutics funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONExit Apr 2025 $0 Granata Bio
SEEDEquity / VC May 2022 $12M $46M Cambrian BioPharma
SPINOUTOther financing Jan 2021 $0 Harvard Medical School · Massachusetts General Hospital
Showing 3 recorded eventsUnlock the complete deal history →

Financials

Revenue and workforce over time

Available revenue and workforce history. Fields without reported data are omitted.

YearRevenueGrowthEmployees
2026 $100K 0% 1
2025 $100K 0% 1
2024 $100K 0% 3
2023 $100K 0% 5
2022 $100K 2
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Oviva Therapeutics website traffic

Latest recorded traffic for Oviva Therapeutics is 3.2K monthly website visits, up 100% over the last three months. Oviva Therapeutics's team grew 0% over the past year.

Latest monthly visits3.2K 3-month web change+100% 1-year team growth0%
Monthly website visits40 observations · Nov 2022–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Oviva Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Muvon TherapeuticsMuvon Therapeutics is creating an autologous cell therapy for damaged skeletal muscles in SUI patients, with a primary focus on developing a safe treatment for stress urinary incontinence in women Zurich, Switzerland Operational 16 $19M $55M
Smart ImmuneDevelops off-the-shelf allogeneic T-cell progenitor therapies to restore a fully functional immune system in patients with cancer and severe infections Paris, France Operational
Galilei BiosciencesDrug development company targeting a central regulator of DNA damage repair, as well as glucose and lipid metabolism, driving metabolic health and human longevity Cambridge, United States Operational
DISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds Cologne, Germany Operational
Ysotope TheranosticsTargeted radiopharmaceuticals for precision oncology Madrid, Spain Operational
Vasa TherapeuticsPrecision medicine for heart failure and healthy aging Encinitas, United States Operational
MitoRx TherapeuticsBiotechnology company developing novel therapeutics that reverse mitochondrial dysfunction Exeter, United Kingdom Operational
AviadoBioPrecision gene therapies for neurodegenerative disorders London, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Talent graph

Oviva Therapeutics's talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Oviva Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
Cambrian BioPharma
Other known 3 additional known investors
Granata Bio
Harvard Medical School
Massachusetts General Hospital

Global footprint

Where Oviva Therapeutics has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

In the news

Latest news about Oviva Therapeutics

Recent press, funding announcements, and product moves mentioning Oviva Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Oviva Therapeutics

An AI-synthesized read of the highest-engagement posts about Oviva Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oviva Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.